http://purl.org/np/RAqC1DEyLf... RAqC1DEyLf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-07-03T12:42:36.110Z

http://purl.org/np/RAqC1DEyLf... RAqC1DEyLf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

rapivab is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than two days 1 limitations of use efficacy based on clinical trials in which the predominant influenza virus type was influenza a a limited number of subjects infected with influenza b virus were enrolled 1 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use 1 efficacy could not be established in patients with serious influenza requiring hospitalization 1 limitations of use efficacy of rapivab is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza a virus a limited number of subjects infected with influenza b virus were enrolled influenza viruses change over time emergence of resistance substitutions could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use rapivab see microbiology 12 4 the efficacy of rapivab could not be established in patients with serious influenza requiring hospitalization see clinical studies 14 3

Leoni Bücken

2021-07-03T12:42:36.110Z

http://purl.org/np/RAqC1DEyLf... RAqC1DEyLf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_8469 DOID_8469

Leoni Bücken

2021-07-03T12:42:36.110Z

http://purl.org/np/RAqC1DEyLf... RAqC1DEyLf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-07-03T12:42:36.110Z

http://purl.org/np/RAqC1DEyLf... RAqC1DEyLf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB06614 drugbank:DB06614

Leoni Bücken

2021-07-03T12:42:36.110Z

http://purl.org/np/RAqC1DEyLf... RAqC1DEyLf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-07-03T12:42:36.110Z

http://purl.org/np/RAqC1DEyLf... RAqC1DEyLf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-07-03T12:42:36.110Z

http://purl.org/np/RAqC1DEyLf... RAqC1DEyLf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-07-03T12:42:36.110Z